Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China
BEIJING and PRINCETON, N.J., Jan. 11, 2022 /PRNewswire/ -- Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics in China. Clario, formerly...
SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study
BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT04994795). Since officially launching last month, 12 sites across 5 countries have...
Qilian International Holding Group Limited Releases 2022 Chairman Letter
JIUQUAN, China, Jan. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today released a letter to shareholders from the Chairman of the Company's board of directors. Dear Shareholders, As a well-established manufacturer with a long history in the Chinese pharmaceuticals and...
China’s 2021 U.S. Patent Grants Surged, Even as Total Patent Awards Trended Downward, According to Analysis by IFI CLAIMS
2021 Rankings Shed Light on Corporate R&D Priorities: Telemedicine, Supply Chain Efficiencies, E-Cigs and Artificial Intelligence Among Hottest Areas of Activity NEW HAVEN, Conn., Jan. 11, 2022 /PRNewswire/ -- Enhancements in telemedicine, more hardy grains to feed the world in a time of climate change, and tools to improve the supply chain and better track goods from cargo port to...
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group in China and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and...
Latest Study Shows Encouraging Results of CanSinoBIO’s Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that Preprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of CanSinoBIO's Recombinant COVID-19 Vaccine（Adenovirus Type 5 Vector）for Inhalation Convidecia™as a heterologous booster1. The results of the...
SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections
COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabling the company to initiate the first clinical trial in humans with SNIPR001. The trial, which is scheduled...
MGI Aims to Boost its Market Share through Participation at Expo 2020 Dubai’s Guangdong Week
DUBAI, UAE, Jan. 11, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) is aiming to boost its market share in the Middle East and Asia through participation at Guangdong Week, a dedicated event taking place at the world exhibition's China Pavilion from January 11-13. The biotech company, which is headquartered in Shenzhen, Guangdong, China, will...
Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod
Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy Frequent testing with Circle HealthPod prevents major outbreaks and keeps your home safe HONG KONG, Jan. 11,...
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT05107778) is a multi-center, randomized, single-blind, placebo-controlled study in China to evaluate safety and...
